RWD86 Characteristics of Patients with Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Who Received Pembrolizumab as Part of an Early Access Program in Accordance with KN-355 Labelling
Abstract
Authors
L. Cagnan A. Hakmé N. Bénard L. Bensimon O. Tredan